Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in EnglandResearch in context

Effectiveness of the Sanofi/GSK (VidPrevtyn Beta) and Pfizer-BioNTech (Comirnaty Original/Omicron BA.4-5) bivalent vaccines against hospitalisation in EnglandResearch in context

Summary: Background: The Sanofi/GSK AS03-adjuvanted (VidPrevtyn Beta) vaccine and the Pfizer-BioNTech mRNA (Comirnaty Original/Omicron BA.4-5) bivalent vaccine were offered to adults aged 75 years and over in England from 3rd April 2023. This is the first time an adjuvanted COVID-19 vaccine has bee...

Full description

Bibliographic Details
Main Authors: Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Gavin Dabrera, Mary Ramsay, Jamie Lopez Bernal
Format: Article
Language:English
Published: Elsevier 2024-05-01
Series:EClinicalMedicine
Subjects:
Test-negative case–control
Vaccine effectiveness
COVID-19
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537024001664

Internet

http://www.sciencedirect.com/science/article/pii/S2589537024001664

Similar Items